New research suggests that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a major health publication demonstrates that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs should be cognizant of the danger of fast rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight in about a year and a half.
Weighing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
Researchers point out that individuals who lose weight through dieting typically see a slower weight regain—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Doctors believe the mode of action of the drugs is key to understanding the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Condition?
Health authorities recommend the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the persistent character of excess weight," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have discontinued the jabs explain a sudden return of cravings.
"I experienced a switch flipping and I was suddenly starving," recalled an individual.
The struggle is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Growing Interest
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on combined lifestyle changes.
